BLISSGVS: Strong Q1 FY26 growth in revenue and profit, with key subsidiary divestment completed

About this update from Bliss Gvs Pharma Limited

Revenue and net profit grew year-over-year, with consolidated Q1 FY26 net profit at ₹4,303.79 lakh and revenue at ₹20,746.92 lakh. The company completed a major subsidiary sale and continued ESOP allocations.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Bliss Gvs Pharma Limited